Here are the DEF 14A proxy statements from Baxter International Inc. (BAX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow BAX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BAX filings page.
Baxter International Inc. is asking stockholders to vote at its virtual 2026 annual meeting on May 5, 2026 on five items: electing nine directors, an advisory say-on-pay for 2025, ratifying PricewaterhouseCoopers as auditor, approving a Second Amended and Restated 2021 Incentive Plan, and amending its charter to lower the Board’s minimum size from nine to seven directors.
The company highlights completion of the Kidney Care business sale to Carlyle for about $3.3 billion of net after-tax proceeds, launch of new monitoring and communications products, and recovery of its North Cove facility after Hurricane Helene. Baxter reports 2025 continuing-operations net sales of $11.2 billion, Adjusted EPS of $2.27, GAAP EPS of ($1.75), operating cash flow of $951 million and free cash flow of $438 million, all used in its pay-for-performance programs.
Governance changes include appointing Andrew Hider as President and CEO in August 2025, separating the Chair and CEO roles with Brent Shafer as Non-Executive Chair, adding director Michael McDonnell, refreshing committee leadership, and maintaining strong stockholder rights, board independence and extensive investor engagement.